#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Infantile spasms Mantle cell lymphoma stage II Bronchiectasis Lymphatic malformation Chronic graft versus host disease in intestine Cutaneous T-cell lymphoma stage I Thymic carcinoma Primary immunodeficiency syndrome Acute myeloid leukaemia Encephalitis autoimmune Li-Fraumeni syndrome Chronic myeloid leukaemia Netherton's syndrome Breast cancer metastatic Glomerulonephritis More trials…

    Learn about Rare Diseases

    Glycogen storage disease type V – Basic Information Biotinidase deficiency – Treatment Glycogen storage disease type I – Treatment Alternating hemiplegia of childhood – Life with Disease Systemic mastocytosis – Basic Information Alport’s syndrome Soft tissue sarcoma – Treatment Malignant fibrous histiocytoma – Life with Disease Myxofibrosarcoma – Treatment Propionic acidaemia – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Phosphocreatine Sodium Doxycycline Hyclate Colistimethate Sodium Sonidegib Bleomycin Soya-Bean Oil Refined Gallium (68Ga) Psma-R2 Denosumab Everolimus Granisetron Dalbavancin Efpegerglucagon Gsk3915393 Hst-1011 Pp1493 Datopotamab Deruxtecan Remimazolam Bosentan Odevixibat Rbl012.2 More therapies…

    Learn about Your Condition

    Cardiomyopathy Small intestine adenocarcinoma Pyoderma Endometrial cancer metastatic Osteosarcoma Lymphoma Hypoxia Neurofibromatosis Acute cardiac event Thrombolysis Peripheral ischaemia Crigler-Najjar syndrome Combined immunodeficiency Acute HIV infection Varicella More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer male

  • Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer female
    • Breast cancer male
    • Triple negative breast cancer
    Investigated Drugs:
    • Pembrolizumab
    • Sacituzumab Govitecan
    Germany Poland

  • Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer stage I
    • Breast cancer female
    • Breast cancer male
    Investigated Drugs:
    • Pembrolizumab
    • Sacituzumab Govitecan
    Germany

  • Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Ds-3939A
    Belgium France Spain

  • Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elacestrant
    • Ribociclib
    Austria Germany Spain

  • Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Breast cancer female
    • Breast cancer male
    Investigated Drugs:
    • Olaparib
    • Pembrolizumab
    Germany

  • Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer stage I
    • Breast cancer female
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Cisplatin
    Austria Belgium France Germany Ireland Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!